miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• SET domain containing protein 2 (SETD2) inactivation is frequent in clear cell renal cell carcinoma (ccRCC).
• The post-transcriptional regulation of SETD2 in ccRCC remains poorly understood.

Purpose of the Study:

• To investigate the role of microRNA (miRNA) in regulating SETD2 expression in ccRCC.
• To elucidate the downstream regulatory mechanisms of SETD2 in ccRCC progression.

Main Methods:

• Analysis of SETD2 and miR-106b-5p expression in ccRCC tissues and cell lines.
• Luciferase reporter assays to confirm direct interaction between miR-106b-5p and SETD2.
• Cell cycle analysis, proliferation assays, apoptosis assays, and Western blotting to assess cellular effects.
• Chromatin immunoprecipitation (ChIP) assays to evaluate H3K36me3 binding and p53 activity.

Main Results:

• SETD2 is downregulated in ccRCC and inversely correlated with high miR-106b-5p expression.
• miR-106b-5p directly targets SETD2 mRNA, reducing its protein levels.
• Inhibition of miR-106b-5p induces G0/G1 cell cycle arrest, suppresses proliferation, and promotes apoptosis in ccRCC cells.
• SETD2 downregulation reverses the pro-apoptotic effects of miR-106b-5p inhibition.
• miR-106b-5p antagomir treatment enhances p53 activity via increased H3K36me3 binding to the p53 promoter.

Conclusions:

• This study identifies miR-106b-5p as a key post-transcriptional regulator of SETD2 in ccRCC.
• SETD2 functions as a tumor suppressor in ccRCC by influencing cell cycle, proliferation, and apoptosis.
• The findings reveal a novel regulatory pathway involving SETD2, H3K36me3, and p53 in ccRCC pathogenesis.